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Abstract
Background: Hyperglycemia is a frequent and important metabolic derangement that accompanies severe sepsis
and septic shock. Matrix-Metalloproteinase 9 (MMP-9) has been shown to be elevated in acute stress hyperglycemia,
chronic hyperglycemia, and in patient with sepsis. The objective of this study was to examine the clinical and
pathogenic link between MMP-9 and blood glucose (BG) levels in patients with early severe sepsis and septic shock.
Methods: We prospectively examined 230 patients with severe sepsis and septic shock immediately upon hospital
presentation and before any treatment including insulin administration. Clinical and laboratory data were obtained
along with blood samples for the purpose of this study. Univariate tests for mean and median distribution using
Spearman correlation and analysis of variance (ANOVA) were performed. A p value≤ 0.05 was considered statistically
significant.
Results: Patients were grouped based on their presenting BG level (mg/dL): BG <80 (n = 32), 80–120 (n = 53), 121–150
(n = 38), 151–200 (n = 23), and > 201 (n = 84). Rising MMP-9 levels were significantly associated with rising BG
levels (p = 0.043). A corresponding increase in the prevalence of diabetes for each glucose grouping from 6.3 to
54.1 % (p = 0.0001) was also found. As MMP-9 levels increased a significantly (p < 0.001) decreases in IL-8 (pg/mL)
and ICAM-1 (ng/mL) were noted.
Conclusion: This is the first study in humans demonstrating a significant and early association between MMP-9
and BG levels in in patients with severe sepsis and septic shock. Neutrophil affecting biomarkers such as IL-8 and
ICAM-1 are noted to decrease as MMP-9 levels increase. Clinical risk stratification using MMP-9 levels could
potentially help determine which patients would benefit from intensive versus conventional insulin therapy. In
addition, antagonizing the up-regulation of MMP-9 could serve as a potential treatment option in severe sepsis or
septic shock patients.
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Background
Hyperglycemia is a frequent and important metabolic de-
rangement that can occur in severe sepsis or septic shock.
The up-regulation of several hormones (glucagon, growth
hormone, catecholamines, and glucocorticoids), inflam-
matory mediators (interleukin (IL)-1, IL-6, Intercelluar
Adhesion Molecule (ICAM-1), and tumor necrosis factor
(TNF)-alpha) accompanies the development of hypergly-
cemia [1, 2]. Elevated blood glucose (BG) has been
associated with an increase in oxidative stress, as reflected
by increase in oxygen free radical (O2
. ) generation [3]. In
addition to oxidative stress, there is also inflammatory
stress, because O2
. activates a number of redox-sensitive
pro-inflammatory transcription factors, such as nuclear
factor (NF)-κB, activator protein–1 (AP-1), early growth
response–1 (EGR-1), and hypoxia-inducible factor–α [3, 4].
Insulin administration is not only important in modulat-
ing glycemic control, but it also aids in antagonizing the
pro-inflammatory effects of elevated blood glucose levels
in critically illness. Insulin has been shown to suppress 3* Correspondence: gulsachwani@gmail.com
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important inflammatory mediators: ICAM–1, monocyte
chemoattractant protein–1 expression, and NF-κB binding
in human aortic endothelial cells in vitro [3, 5, 6].
Several studies attempting to elucidate the molecular
mechanisms of hyperglycemia and sepsis have revealed
elevated levels of Matrix-Metalloproteinase-9 (MMP-9)
[7–12]. MMP-9 is a pro-inflammatory biomarker belong-
ing to a family of zinc-containing endoproteinases that are
implicated in chronic cell remodeling, migration, adhe-
sion, and apoptosis. In humans, MMPs consist of a family
of approximately 26 members including the collagenases
(MMP1, 8, 13), stromelysins (MMP3, 10), matrilysins
(MMP7, 26), and gelatinases (MMP2, 9) [13, 14]. In the
setting of sepsis there is a sequestration of polymorpho-
nuclear neutrophils (PMNs) at the site of infection which
is modulated through the processing of various cytokines
and chemokines, in particular IL-8 and ICAM-1. MMP-9
is released by activated PMNs at the site of infection
resulting in tissue injury, and further perpetuation of the
vicious cycle of inflammation and tissue destruction [15].
Despite the abundance of literature in animal and hu-
man models describing the association of elevated MMP-
9 levels with two distinct entities such as hyperglycemia
and sepsis, the link between BG and MMP-9 levels in
humans with severe sepsis and septic shock has not been
described. The aim of our study was to examine the clin-
ical and pathogenic link between MMP-9 and BG levels in
patients with early severe sepsis and septic shock.
Methods
Patients
After obtaining approval by the Henry Ford Health Sys-
tem Institutional Review Board (IRB) we conducted a pro-
spective observational study in a tertiary care, university
affiliated hospital. Patients included in the study presented
to the emergency department (ED) from 1997 to 2000 and
were diagnosed with severe sepsis or septic shock. Blood
samples (serum and plasma) were collected, spun, and
stored at −80 °C upon presentation prior to the adminis-
tration of any therapy including insulin. Patients’ baseline
characteristics, including basic demographics, comorbidi-
ties, presenting clinical data, and Acute Physiology and
Chronic Health Evaluation II (APACHE II) admission
scores were recorded. Patients were grouped by glucose
levels based on recommendations in the literature for gly-
cemic control in critical illness during the study period.
MMP-9, IL-8, & ICAM-1 immunoassays
Biomarker assays were independently performed by Bio-
site, Inc. (Alere), San Diego, Calif. Assays were performed
using immunometric (sandwich) assays performed with
NeutrAvidin-coated 384-well block microtiter plates
(Pierce Biotechnology, Inc.; Rockford, Ill) and a Genesis
RSP 200/8Workstation (Tecan US, Inc., Durham, NC).
Each sample was tested in duplicate. Before performing
any assays, biotinylated primary antibody was diluted in an
assay buffer containing 10 mmol/L tris(hydroxymethyl)-
amino-methane HCl (pH 8.0), 150 mmol/L sodium ch-
loride, 1 mmol/L magnesium chloride, 0.1 mmol/L zinc
chloride, and 10 mL/L polyvinyl alcohol (9Y10 kDa). The
concentration of biotinylated antibody was predetermined
by titration. The primary antibody (10 2 L per well) was
added to the plates and incubated. After washing, 10 g/L
bovine serum albumin and 1 g/L sodium azide were added
to the plate wells that were then incubated at room
temperature. Next, the plates were washed three times
with borate-buffered saline containing 0.02 % polyoxyethy-
lene (20) sorbitan monolaurate (BBS-Tween).
Ten-microliter aliquots of each sample were added to
each plate well, and the plates were incubated. Following
this incubation, the plates were washed three times and al-
kaline phosphatase-conjugated antibody (10 2 L per well)
was added to each plate well and further incubated. The
concentration of the alkaline phosphatase-conjugated
antibody was predetermined to ensure a linear profile in
the dynamic range of interest. After additional incubation,
the plates were washed nine times with BBS-Tween. Atto-
Phos substrate (S1011; Promega Corporation, Madison,
Wis), a fluorescence-enhancing substrate previously di-
luted in AttoPhos buffer (S1021; Promega), was then
added to aid in the measurement of the activity of
antibody-conjugated alkaline phosphatase bound in each
well. The plates were then scanned in a fluorometer
(Tecan Spectrafluor; Tecan US, Inc.) using an excitation
wavelength of 430 nm and an emission wavelength of
570 nm. Each well as scanned six times at 114-second
intervals, and the rate of fluorescence generation was
calculated.
Statistical methods
Descriptive statistics were used to analyze comorbidities,
baseline clinical data, organ dysfunction scores, and
mortality. All continuous variables are expressed as
mean ± standard deviation (STDE). We also performed a
univariate test for means and median distribution using
Spearman correlation and analysis of variance (ANOVA).
A p value < 0.05 was considered statistically significant.




A total of 230 patients with severe sepsis and septic
shock presenting to the ED were included in the study.
Patients were grouped based on presenting BG levels as
follows: <80 mg/dL: n = 32; 80–120 mg/dL: n = 53; 121–
150 mg/dL: n = 38; 151–200 mg/dL: n = 23; >201 mg/dL:
n = 84 (Table. 1). The age of the overall study population
Sachwani et al. Journal of Inflammation  (2016) 13:13 Page 2 of 8
was 66 ± 17.2 years and the gender distribution was
53:47 (Male: Female). The mean APACHE II score of all
patients was 22 ± 7. The baseline demographics for each
BG group are shown in Table 1. The age, race, and gen-
der distributions were similar among the BG groupings.
The rates of pre-existing conditions such as hyperten-
sion, chronic obstructive pulmonary disease (COPD),
and congestive heart failure (CHF) were similar among
the BG groups. However, there was an increase in the
prevalence of diabetes mellitus (DM) as BG levels in-
creased (p = 0.0001). The prevalence of DM was 6.3 %
(n = 2) in the low BG group (<80 mg/dL) and increased
to 54.1 % (n = 46) in the high BG group (>201 mg/dL).
Although not statistically significant, patients in the low
BG group (<80 mg/dL) and 80–120 mg/dL group had
higher rates of pre-existing liver failure (31.3 % and 33 %
respectively) when compared to other BG groups. In
addition, patients in the low BG group were noted to
have a higher incidence of pre-existing renal failure
(18.8 %). A significant difference in APACHE II score on
ED admission was observed between patients in the vari-
ous BG groupings (p = 0.019). APACHE II scores were
highest in the <80 mg/dL BG group (23.8 ± 6.9) and in
the 151–200 mg/dL group (24 ± 7.2).
BG levels and basic clinical data upon ED presentation
Table 2 summarizes baseline vital signs and routine la-
boratory findings. The mean heart rate (HR), systolic
blood pressure (SBP), and respiratory rate (RR) were simi-
lar among the groups. Patients with <80 mg/dL had lower
body temperatures (34.8 °C ± 3.4 °C; p = 0.017) and higher
central venous pressures (CVP; 8.95 mmHg ± 9.5 mmHg;
p < 0.0001) when compared to the other BG groupings.
The mean glucose levels (mg/dL) for each BG group were
as follows: <80: 46 ± 25; 80–120: 100 ± 12; 121–150: 133 ±
8; 151–200: 173 ± 14; and >201: 543 ± 428. ANOVA re-
vealed a statistically significant difference in the mean BG
values (P < 0.0001). Lactate levels were noted to be highest
in the <80 mg/dL (10.1 mg/dL ± 5.1 mg/dL). An increase
in lactate levels were noted in the subsequent BG group-
ings (range 5.5 mg/dL ± 4.7 mg/dL to 7.3 mg/dL ± 4.2 mg/
dL; p < 0.002). Consistent with the presence of infection,
the >201 mg/dL BG group had the highest WBC count
(16 mm3 ± 8.8 mm3), culture positivity (80 %) and
bacteremia rates (42.4 %).
Association between BG, MMP-9, IL-8, and ICAM-1
Figure 1 demonstrates the relationship of BG with
MMP-9, IL-8, and ICAM-1 levels. Rising MMP-9 levels
were significantly associated with rising BG levels (p =
0.043). For the various BG (mg/dL) groupings MMP-9
levels (ng/mL) were as follows: <80: 661, 80–120: 631,
121–150: 802, 151–200: 838, and >201: 898. As MMP-9
levels increased with rising BG levels a statistically sig-
nificant decrease in IL-8 and ICAM-1 levels was noted
(P < 0.0001). For each BG (mg/dL) group the IL-8 (pg/mL)
levels were as follows: : <80: 107, 80–120: 67, 121–150: 34,
151–200: 49, and >201: 31. Similarly, a significant inverse
relationship was observed for ICAM-1 levels (ng/mL) for
each BG group: <80: 450, 80–120: 289, 121–150: 282,
151–200: 256, and >201: 250.
Table 1 Patient basic demographics and comorbidities per Glucose Grouping
Variable All patients <80 mg/dL 80–120 mg/dL 121–150 mg/dL 151–200 mg/dL >201 mg/dL P value
n 230 32 53 38 23 84
Age (years ± SD) 66 ± 17 63 ± 17 59 ± 25 70 ± 15 70 ± 13 66 ± 16 0.08
Gender (M:F) % 53:47 44:56 68:32 50:50 56:44 49:51 0.18
Race, n (%)
AA 201(87) 31(97) 47(89) 32(84) 20(87) 71(85) 0.56
Caucasian 26(11) 1(3) 6(11) 5(13) 3(13) 11(13)
Other 3(1) 1(3) 2(2)
Pre-existing conditions, n (%)
Hypertension 153(67) 22(69) 29(54) 25(64) 14(61) 63(74) 0.2
COPD 34(15) 5(16) 6(11) 10(26) 3(13) 10(12) 0.3
CHF 82(36) 12(37) 22(41) 12(31) 10(43) 26(31) 0.6
Diabetes Mellitus 57(25) 2(6) 3(6) 2(5) 4(17) 46(54) 0.0001
Liver failure 63(27) 10(31) 18(33) 8(20) 5(22) 22(26) 0.6
Renal failure 33(14) 6(19) 6(11) 7(18) 3(13) 11(13) 0.8
APACHE II, mean ± SD 22 ± 7 24 ± 7 19 ± 6 22 ± 7 24 ± 7 21 ± 7 0.019
M Male, F, Female, AA African American, COPD Chronic obstructive pulmonary disease, CHF Congestive heart failure
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Discussion
To our knowledge this is the first study to establish a
significant association between BG levels and MMP-9
levels in patients with severe sepsis or septic shock. In
addition, we also demonstrate that as BG increased an
inverse relationship between MMP-9 and IL-8 levels,
and MMP-9 and ICAM-1 levels was observed.
Currently, it is well-known that in severe sepsis and
septic shock patients, hyperglycemia develops due to a
combination of several factors: 1) Insulin clearance is in-
creased leading to a reduction in insulin-mediated glucose
uptake; 2) Stress induced elevation in plasma levels of
counter-regulatory hormones, such as catecholamines,
glucagon, cortisol, and growth hormone. These hormones
lead to hyperglycemia due to muscle glycolysis and lipoly-
sis, and subsequent gluconeogenesis and glycolysis in the
liver; 3) Hyperlactatemia due to glycolysis in muscle
caused by the counterregulatory hormones and cytokines,
sometimes referred to as the “lactate shuttle” 4) Insulin re-
sistance which could be due to a defective GLUT4 trans-
porter and to the deleterious effects of pro-inflammatory
cytokines such as IL-1, IL-6, and TNF-α [16–18].
It has been demonstrated via various significant in vivo
and in vitro experimental studies that in the setting of
acute or chronic hyperglycemia (diabetes mellitus), glu-
cose can induce the increase of pro-inflammatory tran-
scription factors such as NF-kB, AP-1, and EGR-1. The
MMP-9 promoter region has been described to contain
responsive elements to the aforementioned transcription
factors and thus up-regulating MMP-9 transcription and
activity [5, 10, 19, 20]. Our results may suggest a possible
up-regulation of MMP-9 in the setting of both acute and
Table 2 Patient clinical and routine laboratory findings upon presentation
Variable (mean ± SD) <80 mg/dL 80–120 mg/dL 121–150 mg/dL 151–200 mg/dL >201 mg/dL P value
Temperature, °C 34.8 ± 3.4 36.5 ± 2.9 35.8 ± 2.5 36.3 ± 3.1 36.8 ± 2.5 0.017
HR, beats/min 106 ± 30 120 ± 26 115 ± 33 117 ± 34 120 ± 29 0.22
SBP, mmHg 106 ± 37 107 ± 36 96 ± 27 97 ± 33 113 ± 35 0.079
CVP, mmHg 8.95 ± 9.5 9.3 ± 8.5 4.3 ± 8.9 2.8 ± 6.2 1.96 ± 6.2 <0.0001
Glucose, mg/dL 46 ± 25 100 ± 12 133 ± 8 173 ± 14 543 ± 428 <0.0001
Lactate, mg/dL 10.1 ± 5 5.5 ± 4.7 5.9 ± 3.5 7.1 ± 5.1 7.3 ± 4.2 0.002
WBC, mm3 12 ± 10 11 ± 8 15 ± 10 15 ± 8 16 ± 9 0.008
Anion Gap, mM/L 24 ± 8 19 ± 9 20 ± 5 20 ± 6 23 ± 8 0.003
ScvO2, % 61 ± 24 49 ± 18 49 ± 15 48 ± 10 55 ± 10 0.2
BUN, mg/dL 44 ± 26 41 ± 36 50 ± 29 53 ± 29 46 ± 33 0.53
Creatinine, mg/dL 3 ± 2 2 ± 2 3 ± 2 3 ± 2 2 ± 2 0.22
Positive Blood Culture, n (%) 22(69) 42(78) 30(77) 16(70) 68(80) 0.7
Bacteremia, n (%) 13(41) 15(28) 14(36) 8(35) 36(43) 0.5
°C Degrees Celsius, HR Heart Rate, SBP Systolic Blood Pressure, CVP Central Venous Pressure, WBC White Blood Cell, ScvO2 Central Venous Oxygen Saturation,
BUN Blood Urea Nitrogen
Fig. 1 Association of increasing MMP-9 (grey bars) levels with increasing blood glucose (BG) levels. Inverse proportional association of IL-8
(┈■┈) and ICAM-1 (—▲—) with MMP-9 levels
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chronic hyperglycemia. The majority of patients with BG
ranging from 121 mg/dL to 200 mg/dL had increased
MMP-9 levels most likely secondary to an acute increase
in their BG levels in the setting of critical illness. This is
inferred from the study data as the prevalence of DM in
patients with a BG ranging from 121 mg/dL to 200 mg/dL
was only 5 % to 17 %. Consistent with the literature, the
highest MMP-9 level (898 ng/mL) was noted in patients
in the high BG (>201 mg/dL) group. This group had the
highest mean BG level (543 mg/dL ± 428 mg/dL) upon
presentation to the ED and it also had the highest preva-
lence of DM (56 %).
High MMP-9 levels have been identified in patients in
severe sepsis or septic shock. In addition to the up-
regulation of MMP-9 gene transcription secondary to pro-
inflammatory factors, MMP-9 levels are increased in the
setting of sepsis due to the release of MMP-9 by activated
PMNs at the site of infection causing tissue injury and fur-
ther perpetuating the vicious cycle of inflammation and
tissue destruction [15, 21]. The significant rise of MMP-9
across the BG groupings in this study cannot solely be at-
tributed to acute (stress) or chronic hyperglycemia. In our
study patients with low BG (<80 mg/dL) or normogly-
cemia (80–120 mg/dL) still had elevated MMP-9 levels
(661 ng/mL and 631 ng/mL respectively) leading us to the
conclusion that the MMP-9 elevation in these two groups
is probably due to the increase in neutrophil activation
rather than stress response or chronic hyperglycemia [22].
The rise in MMP-9 levels in patients with severe sepsis
or septic shock has been described to occur very early in
the disease process. In an experimental study involving
human subjects Albert et al., demonstrated that MMP-9
levels peaked 2 h after the administration of bacterial
lipopolysaccharide (LPS) [23]. Nakamura et al., provided
the first report of elevated plasma MMP-9 levels in 20
patients with septic shock. They were able to demon-
strate that plasma MMP-9 concentrations were signifi-
cantly higher in the non-surviving patients with septic
shock than in the surviving patients with septic shock
[24]. Since then, various studies have corroborated the
increase of MMP-9 levels in patients with severe sepsis
or septic shock and their poor outcomes [11, 12, 25–27].
In one of our previous study in which we described the
natural history of circulatory biomarker activity in the
most proximal phases of severe sepsis and septic shock
we also noted that MMP-9 levels peaked early (6 h) after
presentation [28].
The rise of MMP-9 in septic patients can be due to: 1)
genetic up-regulation and 2) release by activated neutro-
phils. Together with MMP-9 levels we measured the
levels of two biomarkers (IL-8 and ICAM-1) intimately
involved with neutrophil function. IL-8, a member of the
CXC chemokine family has been reported to be elevated
and play a role in the pathophysiology of sepsis because
of its ability to attract, activate and degranulate neutro-
phils [29, 30]. In addition, the expression of ICAM-1 (a
cell surface glycoprotein) is increased on the cell surface
of neutrophils allowing it to attach and migrate through
the endothelium during sepsis [31, 32]. Our results dem-
onstrate the existence of an inverse relationship between
MMP-9 and IL-8 as well as MMP-9 and ICAM-1 as BG
levels increased. A possibility behind the inverse rela-
tionship noted between MMP-9 and IL-8 is that MMP-9
is known to cleave a specific site of IL-8 molecular struc-
ture rendering a variant IL-8 molecule which is 10 to 30
fold more potent in neutrophil activation [33, 34]. We
theorize that our assay provided us with the measure-
ment of the native IL-8 molecule and not the variant IL-
8 form which we conceptually believe to be elevated.
The aforementioned observation describes the relation-
ship between IL-8 and MMP-9 from a proteonomic and
metabolomic point of view. However, the possibilities of
genomic links between IL-8 and MMP-9 needs to be
further investigated. To explain the relationship between
ICAM-1 and MMP-9 is more challenging as there is a
scarcity of studies describing this relationship. In the
field of oncology MMP-9 has been shown to proteolytic-
ally cleave the extracellular domain of ICAM-1 leading
to its release from the cell surface [35]. Thus, it would
lead us to believe that ICAM-1 levels should in fact rise
as MMP-9 levels increase. Our observation contrast this
finding. A possible explanation to the rise of MMP-9
and decrease of ICAM-1 levels may be due to the direct
effect of insulin on such biomarkers. Aljada et al., demon-
strated that insulin inhibits the expression of ICAM-1 in
human aortic endothelial cells mediated by an increase in
nitric oxide (NO) release and nitric oxide synthase (NOS)
expression [36]. On the other hand, Fischoeder et al.,
described that insulin was a potent inducer of MMP-9
activity in primary human monocytes [37].
The early pathogenic link between elevated MMP-9
levels and elevated BG levels make it plausible to con-
sider that early inhibition or removal of this biomarker
may have therapeutic potential. Antibiotics, such as the
tetracyclines inhibit MMPs, not only by chelating the
zinc and calcium ions but also by affecting the induction
of the MMP genes. The therapeutic administration of
tetracyclines over prolonged periods of time may cause
undesirable side effects, such as gastrointestinal distur-
bances and emergence of antibiotic resistance. A recent
pilot study reported a low side effect profile of doxycyc-
line (tetracycline) based on sub-antimicrobial concentra-
tions dosing (100 mg intravenous (IV) daily, followed by
50 mg IV once daily for 2 days). However, their results
showed no effect on MMP-9 levels [38]. The chemically
modified tetracyclines (CMT), which lack antibacterial
activity but retain the associated anti-inflammatory
properties of tetracyclines are the preferred MMP
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inhibitor because they offer several advantages over con-
ventional tetracyclines. The CMT have been proposed to
induce no gastrointestinal side effects or toxicities, attain
higher concentrations in plasma, and cross the blood–
brain barrier and blood-retina barrier [39]. In an animal
model for sepsis, Maitra et al., demonstrated that MMP-
9 levels together with glutamic oxaloacetic acid trans-
aminase (GOT), glutamic pyruvic transaminase (GPT),
and nitric oxide (NO) were decreased when septic rats
were pre-treated with CMT 24 h and 1 h prior to cecal
ligation and puncture (CLP) [40]. They also reported
that the 24 h mortality rates for CLP rats were much
higher in the untreated group (30 %) when compared to
the CMT pretreatment group in which no deaths were
reported. In this case, the prophylactic administration of
CMT in the setting of sepsis has shown to effectively de-
crease MMP-9 levels and improve survival. However, the
more clinical relevant question is to determine the ap-
propriate treatment window in which CMTs can be ad-
ministered in order to decrease MMP-9 levels, improve
survival, and decrease the sequela of sepsis (i.e. ARDS;
liver failure). Halter et al., performed an animal study to
test the hypothesis of a treatment window during which
CMT could be administered in the setting of sepsis. Even
though they did not specifically measure MMP-9 levels,
they discovered that CMT given at 6 and 12 h after CLP
improved survival and lung injury rates when compared
to the group that received CMT at 24 h. Therefore,
Halter’s group concluded that CMT can be adminis-
tered as late as 12 h after septic insult [41].
Another alternative that has shown to decrease circu-
lating levels of MMP-9 and improve survival in the
setting of sepsis is the use of hemoperfusion using poly-
mixin B immobilized on fibers (PMX-F). Nakamura et
al., demonstrated that hemoadsorption therapy using
PMX-F columns decreased the level of circulating
MMP-9 and improved the survival rate of the patients
with septic shock. They hypothesized that hemoperfu-
sion therapy with PMX-F attenuated the increase in
plasma MMP-9 concentrations in patients with septic
shock by reducing plasma endotoxin [24].
Much controversy has been generated in regards to gly-
cemic control since the landmark article of van den
Berghe et al., which demonstrated decreased mortality in
critically ill patients treated with intensive insulin therapy
[42]. Since then, several RCTs and meta-analyses have
emerged revealing no mortality benefits in critically ill pa-
tients initiated on an intensive insulin therapy [43–48]. In
fact, the NICE-SUGAR trial demonstrated an increase in
mortality in patients undergoing intensive glucose control
(BG level target ≤ 110 mg/dL) when compared to the group
treated with a BG target of 180 mg/dL [49]. In order to
achieve adequate BG control in septic patients a different
approach may need to be undertaken. This study shows a
close association between elevated pro-inflammatory
cytokines and the development of hyperglycemia in severe
sepsis and septic shock patients. Therefore, adjusting treat-
ment based on the level of pro-inflammatory cytokines may
be an option for adequate glucose control [50, 51]. Naka-
mura et al., demonstrated a significant positive correlation
between a pro-inflammatory cytokine (IL-6) and BG level
in septic patients. Their results showed that the rate of
successful glucose control decreased with an increase in
the blood IL-6 level and that in the failed glucose control
group the insulin dose per 100 kcal energy intake was
higher [51]. Keeping in mind the concept of hypercytoki-
nemia and hyperglycemia in septic patients together with
the results reported by Fischoeder et al., in which insulin
was found to be a potent inducer of MMP-9 activity in
primary human monocytes [37], we hypothesize that
MMP-9 levels may serve as a marker to help stratify septic
patients to an intensive versus conventional insulin ther-
apy group. We believe that patients with elevated MMP-9
and BG levels may be stratified to a conventional insulin
therapy group (BG target of 180 mg/dL) and insulin
should be judiciously used to avoid further release of
MMP-9 as this will subsequently increase the rate of
extracellular matrix (ECM) remodeling and its sequelae.
Notable strengths of this study include the large num-
ber of patients recruited and the ability to measure
MMP-9 levels very early in the disease process. The
MMP-9 levels were measured upon presentation to our
ED before any treatment (i.e. antibiotics, intravenous
fluids, or insulin) was initiated. Together with the con-
ventional therapeutic strategies used for septic patients,
antagonizing the up-regulation of MMP-9 could serve as
a potential treatment option. In order to establish the
use of MMP-9 as a possible biomarker for glucose con-
trol and also as a therapeutic target in septic patients
further prospective trials are required. In addition, more
studies are also required to explain the inverse relation-
ship noted between IL-8 and ICAM-1 with MMP-9.
Conclusion
This prospective observational study in humans demon-
strates a significant and early association between MMP-9
and BG levels in patients with severe sepsis and septic
shock. Neutrophil affecting biomarkers such as IL-8 and
ICAM-1 are noted to decrease as MMP-9 levels increase.
Risk stratification using MMP-9 levels could potentially
help determine which patients would benefit from inten-
sive versus conventional insulin therapy. In addition, antag-
onizing the up-regulation of MMP-9 could serve as a
potential treatment option in severe sepsis or septic shock
patients.
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